Use of sibutramine (Meridia) in obese patients with Type 2 diabetes is associated with statistically significant weight loss and a decreased hemoglobin A1c
2008-10-16
Loading...
View/Download File
Persistent link to this item
Statistics
View StatisticsJournal Title
Journal ISSN
Volume Title
Title
Use of sibutramine (Meridia) in obese patients with Type 2 diabetes is associated with statistically significant weight loss and a decreased hemoglobin A1c
Authors
Published Date
2008-10-16
Publisher
Type
Other
Abstract
Abstract: In a meta-analysis of 8 randomized controlled
trials including obese patients with Type 2 diabetes, the addition of sibutramine to standard diabetes therapy resulted in a significant decrease in body weight and hemoglobin A1c.
Keywords
Description
The information provided in this handout does not necessarily reflect the views of the University of Minnesota Medical School physicians and faculty. These materials are provided for informational purposes only and are in no way intended to take the place of the advice and recommendations of your personal health care provider. You use the information provided in these handouts at your own risk.
Related to
Replaces
License
Series/Report Number
Funding information
Isbn identifier
Doi identifier
Previously Published Citation
Other identifiers
Suggested citation
Sandvig, Lisa. (2008). Use of sibutramine (Meridia) in obese patients with Type 2 diabetes is associated with statistically significant weight loss and a decreased hemoglobin A1c. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/44284.
Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.